- Reviews (0)
|Applications||ELISA FACS IHC WB|
|Antigen/Gene or Protein Targets||CD20|
|Synonyms||B-lymphocyte antigen CD20|
B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity.
In humans CD20 is encoded by the MS4A1 gene. This gene encodes a member of the membrane-spanning 4A gene family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and non-lymphoid tissues. This gene encodes a B-lymphocyte surface molecule that plays a role in the development and differentiation of B-cells into plasma cells. This family member is localized to 11q12, among a cluster of family members. Alternative splicing of this gene results in two transcript variants that encode the same protein.
CD20 is the target of the monoclonal antibodies (mAb) rituximab, obinutuzumab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemia. It has been shown that inhibition of BCR signalling by ibrutinib affects the expression of CD20 and the efficacy of anti-CD20 antibodies.
|Notes||Purified using protein G|
|Research Area||Cancer, Cell Type or Organelle Marker, Immunology|
Have you used this reagent? Share your experience by submitting a review and help your fellow scientists.Review this reagent